Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
Journal of Diabetes Investigation · 2025-06 · 16 (6) · 1028-1033
DOI: 10.1111/jdi.70023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 15.03.2025. Verfasst von Yiming Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Albuminuria, Renal Insufficiency, Chronic, Naphthyridines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
No studies have specifically examined the effects of finerenone in treating type 2 diabetes patients with chronic kidney disease (CKD) and microalbuminuria. This study aimed to evaluate the effectiveness of finerenone in this group of patients.
Methods
This retrospective real‐world study (ChiCTR2400087169) included type 2 diabetes outpatients with CKD from the Peking University First Hospital between March 2023 and March 2024. All patients in this study had a urinary albumin‐to‐creatinine ratio (UACR) of 30–299 mg/g. The effects of finerenone were assessed by comparing UACR, HbA1c, creatinine, serum potassium, eGFR, and blood pressure at baseline and after treatment.
Results
Sixty‐four patients (39 males and 25 females), with a median age of 65.75 years and a median duration of T2DM of 15.21 years, were included. The baseline median UACR was 100.50 mg/g, significantly decreased to 61.27 mg/g ( P < 0.001) at 3 months and 62.49 mg/g ( P < 0.001) at 6 months after treatment. None of the other parameters differed significantly. Finerenone alone or in combination with ABS inhibitors, SGLT2 inhibitors, or GLP‐1 agonists did not result in significant differences in UACR reduction. Patients with a >30% UACR decrease had significantly higher baseline systolic blood pressure (SBP) than those with a ≤30% decrease ( P < 0.05). Furthermore, baseline SBP significantly decreased after 6 months of treatment in patients with a >30% UACR reduction ( P < 0.05).
Conclusions
Finerenone is effective in treating type 2 diabetes with CKD and microalbuminuria. Improved SBP control leads to a greater UACR reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Peking University First Hospital, Beijing, China.
ORCID-Profile: Ang Li
Förderung
- National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital)
Zitieren
APA
Wu, Y., Gao, Y., Guo, X., Zhang, J., & Li, A. (2025). Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study. Journal of Diabetes Investigation, 16(6), 1028-1033. https://doi.org/10.1111/jdi.70023
Vancouver
Wu Y, Gao Y, Guo X, Zhang J, Li A. Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study. Journal of Diabetes Investigation. 2025;16(6):1028-1033. doi:10.1111/jdi.70023
BibTeX
@article{Wu2025,
author = {Wu, Yiming and Gao, Ying and Guo, Xiaohui and Zhang, Junqing and Li, Ang},
title = {Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study},
journal = {Journal of Diabetes Investigation},
year = {2025},
volume = {16},
number = {6},
pages = {1028--1033},
doi = {10.1111/jdi.70023}
}
EUVIMED